[Gynecological Cancers in Patients with Inflammatory Rheumatic Diseases]

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2016 Jan 28

PMID 26813689

Authors

M Schmalzing

M Krockenberger

A Honig

H-P Tony

Affiliations

Soon will be listed here.

Abstract

The risk of gynecological cancers in patients with inflammatory rheumatic diseases only seems to be elevated with respect to cervical cancer and mainly in patients with systemic lupus erythematosus. There is increasing evidence for an influence of the immune system on tumor control of gynecological malignancies; however, an adverse influence of immunosuppressive treatment in rheumatic patients was indicated only for the risk of cervical cancer. In contrast, biologics could not be shown to cause an increased risk of cervical cancer but data on this topic are limited. General screening recommendations exist for breast cancer and cervical cancer. Recommendations for follow-up after oncological treatment are presented. Because of limited evidence immunosuppressive and biological treatment should be applied with great restraint at least within the first 5 years after curative oncological treatment also for gynecological tumors. As far as breast cancer is concerned an even longer interval is under discussion.

References

Hemminki K, Liu X, Ji J, Forsti A, Sundquist J, Sundquist K . Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012; 127(1):180-5. DOI: 10.1016/j.ygyno.2012.07.100. View

Mercer L, Low A, Galloway J, Watson K, Lunt M, Symmons D . Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis. 2012; 72(1):143-4. DOI: 10.1136/annrheumdis-2012-201814. View

Grunfeld E, Dhesy-Thind S, Levine M . Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ. 2005; 172(10):1319-20. PMC: 557103. DOI: 10.1503/cmaj.045062. View

Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler S . Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol. 2008; 180(11):7338-48. PMC: 3607742. DOI: 10.4049/jimmunol.180.11.7338. View

Kash N, Lee M, Kollipara R, Downing C, Guidry J, Tyring S . Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med. 2015; 4(4):614-33. PMC: 4470159. DOI: 10.3390/jcm4040614. View

Cordtz R, Mellemkjaer L, Glintborg B, Hetland M, Dreyer L . Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis. Ann Rheum Dis. 2015; 74(7):1479-80. DOI: 10.1136/annrheumdis-2014-206909. View

Selby P, Gillis C, Haward R . Benefits from specialised cancer care. Lancet. 1996; 348(9023):313-8. DOI: 10.1016/s0140-6736(96)02482-8. View

Klumb E, Araujo Jr M, Jesus G, Santos D, Oliveira A, Albuquerque E . Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?. J Clin Rheumatol. 2010; 16(4):153-7. DOI: 10.1097/RHU.0b013e3181df5261. View

Khatcheressian J, Hurley P, Bantug E, Esserman L, Grunfeld E, Halberg F . Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2012; 31(7):961-5. DOI: 10.1200/JCO.2012.45.9859. View

10.

Kobayashi A, Weinberg V, Darragh T, Smith-McCune K . Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 2008; 1(5):412-20. DOI: 10.1038/mi.2008.33. View

11.

Emens L . Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012; 12(12):1597-611. PMC: 3587160. DOI: 10.1586/era.12.147. View

12.

Raaschou P, Frisell T, Askling J . TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014; 74(12):2137-43. DOI: 10.1136/annrheumdis-2014-205745. View

13.

Kato T, Kakuta Y, Yamanaka K, Okumi M, Abe T, Imamura R . Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience. Springerplus. 2015; 4:196. PMC: 4431989. DOI: 10.1186/s40064-015-0946-2. View

14.

Smitten A, Simon T, Hochberg M, Suissa S . A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008; 10(2):R45. PMC: 2453765. DOI: 10.1186/ar2404. View

15.

Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, Van Walraven C . Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast. 2004; 11(3):228-35. DOI: 10.1054/brst.2001.0404. View

16.

Likes W, Santoso J, Wan J . A cross-sectional analysis of lower genital tract intraepithelial neoplasia in immune-compromised women with an abnormal Pap. Arch Gynecol Obstet. 2012; 287(4):743-7. DOI: 10.1007/s00404-012-2637-3. View

17.

Nguyen M, Flowers L . Cervical cancer screening in immunocompromised women. Obstet Gynecol Clin North Am. 2013; 40(2):339-57. DOI: 10.1016/j.ogc.2013.02.005. View

18.

Ji J, Liu X, Sundquist K, Sundquist J . Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology (Oxford). 2011; 50(8):1513-8. DOI: 10.1093/rheumatology/ker143. View

19.

Rojas M, Telaro E, Russo A, Moschetti I, Coe L, Fossati R . Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005; (1):CD001768. DOI: 10.1002/14651858.CD001768.pub2. View

20.

Hinten F, Meeuwis K, van Rossum M, de Hullu J . HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients. Crit Rev Oncol Hematol. 2012; 84(2):161-80. DOI: 10.1016/j.critrevonc.2012.02.008. View